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BACKGROUND
Combination treatment with the cystic fibrosis transmembrane conductance regu-
lator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed 
to target the underlying cause of disease in patients with cystic fibrosis.
METHODS
In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-
group trial, we evaluated combination therapy with tezacaftor and ivacaftor in 
patients 12 years of age or older who had cystic fibrosis and were homozygous for 
the CFTR Phe508del mutation. Patients were randomly assigned in a 1:1 ratio to 
receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily 
or matched placebo for 24 weeks. The primary end point was the absolute change in 
the percentage of the predicted forced expiratory volume in 1 second (FEV1) through 
week 24 (calculated in percentage points); relative change in the percentage of the 
predicted FEV1 through week 24 (calculated as a percentage) was a key secondary 
end point.
RESULTS
Of the 510 patients who underwent randomization, 509 received tezacaftor–ivacaftor 
or placebo, and 475 completed 24 weeks of the trial regimen. The mean FEV1 at 
baseline was 60.0% of the predicted value. The effects on the absolute and relative 
changes in the percentage of the predicted FEV1 in favor of tezacaftor–ivacaftor over 
placebo were 4.0 percentage points and 6.8%, respectively (P<0.001 for both com-
parisons). The rate of pulmonary exacerbation was 35% lower in the tezacaftor–
ivacaftor group than in the placebo group (P = 0.005). The incidence of adverse 
events was similar in the two groups. Most adverse events were of mild severity 
(in 41.8% of patients overall) or moderate severity (in 40.9% overall), and serious 
adverse events were less frequent with tezacaftor–ivacaftor (12.4%) than with pla-
cebo (18.2%). A total of 2.9% of patients discontinued the assigned regimen owing 
to adverse events. Fewer patients in the tezacaftor–ivacaftor group than in the pla-
cebo group had respiratory adverse events, none of which led to discontinuation.
CONCLUSIONS
The combination of tezacaftor and ivacaftor was efficacious and safe in patients 
12 years of age or older who had cystic fibrosis and were homozygous for the CFTR 
Phe508del mutation. (Funded by Vertex Pharmaceuticals; EVOLVE ClinicalTrials.gov 
number, NCT02347657.)
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Cystic fibrosis is caused by a reduced quantity or function of cystic fibrosis trans-membrane conductance regulator (CFTR) 
protein, owing to mutations in CFTR. A loss of 
chloride secretion causes impaction of mucus in 
the airways, gastrointestinal tract, and exocrine 
organs, with important clinical consequences that 
include progressive loss of lung function, nutri-
tional deficits, pulmonary exacerbations, and 
respiratory failure.1,2 Cystic fibrosis affects more 
than 80,000 persons worldwide. Phe508del is the 
most prevalent CFTR mutation worldwide; approxi-
mately 46% of patients with cystic fibrosis in the 
United States are homozygous for this allele, as 
are 49% of those in Canada and 40% of those in 
Europe.3-6 The Phe508del mutation leads to greatly 
reduced CFTR protein activity owing to impaired 
processing and trafficking of CFTR to the epi-
thelial-cell surface, as well as impaired function 
of the small quantity of the protein that is pro-
duced and trafficked to epithelial membranes.7-9
CFTR modulators are a family of new com-
pounds that target specific defects caused by muta-
tions in CFTR and thereby treat the underlying 
cause of cystic fibrosis. Ivacaftor, a CFTR potentia-
tor and the first approved CFTR modulator, in-
creases the probability of channel opening (i.e., the 
fraction of time that the channels are open) of 
normal and mutant CFTR protein in vitro.10 The 
drug has been approved for use in patients with 
a broad range of CFTR gating and other mutations 
that produce some CFTR protein on the epithelial-
cell surface.11-16 In long-term registry studies, 
ivacaftor has reduced mortality and rates of lung 
transplantation and other complications of cystic 
fibrosis among patients with gating mutations.17 
Lumacaftor, a CFTR corrector, improves pro-
cessing and trafficking of CFTR protein18 and, in 
combination with ivacaftor, is approved for use 
in patients who are homozygous for the Phe508del 
CFTR mutation on the basis of randomized clini-
cal trials that have shown improved lung function 
and nutritional status and a reduced frequency of 
exacerbations.19-22
Ivacaftor and the combination therapy luma-
caftor–ivacaftor have both been associated with 
a rate of progressive decline in lung function that 
is lower than the rate observed among untreated, 
matched, control registry patients, which shows 
that effective CFTR modulators may modify the 
course of disease.19,23 However, not all patients 
who are homozygous for the Phe508del mutation 
can receive lumacaftor–ivacaftor because of its re-
spiratory side-effect profile.24-26 In addition, strong 
cytochrome P-450-3A induction by lumacaftor 
causes prohibitive drug–drug interactions in some 
patients and limits the use of lumacaftor–ivacaftor 
in patients with ivacaftor-responsive mutations.27 
Therefore, new CFTR modulator treatments for 
the population of patients who are homozygous 
for the Phe508del mutation are needed.
Tezacaftor is an investigational CFTR correc-
tor that, in combination with ivacaftor, has shown 
efficacy in preclinical studies28 and has shown 
enhanced CFTR function and improved lung 
function in a phase 2 clinical trial involving pa-
tients who were homozygous for the Phe508del 
mutation or heterozygous for the Phe508del and 
G551D mutations.29 Here, we report the findings 
of a phase 3 trial that evaluated the efficacy and 
safety of tezacaftor in combination with iva-
caftor in patients with cystic fibrosis who were 
homozygous for the Phe508del mutation.
Me thods
Trial Design and Oversight
This phase 3, randomized, double-blind, multi-
center, placebo-controlled, parallel-group trial 
(VX14-661-106, also called EVOLVE) involved 
patients 12 years of age or older with cystic fi-
brosis who were homozygous for the Phe508del 
CFTR mutation. The trial was conducted at 91 sites 
in the United States, Canada, and Europe from 
January 30, 2015, to January 20, 2017. Combination 
therapy with tezacaftor and ivacaftor (VX-661 
and VX-770, respectively; Vertex Pharmaceuticals) 
or placebo was administered for 24 weeks. The 
primary objective was to evaluate the efficacy of 
tezacaftor–ivacaftor as compared with placebo, 
and the safety of tezacaftor–ivacaftor was a sec-
ondary objective. The trial protocol (available with 
the full text of this article at NEJM.org) and in-
formed-consent forms were approved by an inde-
pendent ethics committee or institutional review 
board for each trial site. All the enrolled patients, 
or their parent or legal guardian, provided written 
informed consent; when appropriate, assent was 
obtained from the patients. Safety was monitored 
by an independent data and safety monitoring 
committee that comprised members of the Cystic 
Fibrosis Foundation Data Safety Monitoring Board.
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Patients were randomly assigned in a 1:1 ratio 
to receive either a combination of 100 mg of 
tezacaftor once daily and 150 mg of ivacaftor 
twice daily (administered as a fixed-dose combi-
nation tablet containing 100 mg of tezacaftor 
and 150 mg of ivacaftor in the morning and a 
tablet containing 150 mg of ivacaftor in the eve-
ning) or matched placebo for 24 weeks. The 
tezacaftor–ivacaftor dose regimen was selected 
on the basis of the results of a phase 2 dose-
escalation study.29 Randomization was stratified 
according to age (<18 years vs. ≥18 years), sex, 
and the percentage of the predicted forced expi-
ratory volume in 1 second (FEV1) (<70% vs. ≥70%) 
at screening. At trial completion, patients were 
given the option to enroll in a 96-week open-label 
extension study (VX14-661-110; ClinicalTrials.gov 
number, NCT02565914); patients began the ex-
tension study immediately after completion of the 
24-week trial.
The trial sponsor (Vertex Pharmaceuticals) de-
signed the protocol in collaboration with the au-
thors. Data were collected by local site investiga-
tors (see the Supplementary Appendix, available 
at NEJM.org) and analyzed by the sponsor. All 
the authors had full access to the trial data after 
the data were unblinded. The manuscript was writ-
ten with the assistance of medical writers, with 
funding by the sponsor; all the authors provided 
critical review and input. Final decisions regard-
ing the content of the submitted manuscript were 
made by the first and last authors. All the authors 
made the decision to submit the manuscript for 
publication. The authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol. Confidentiality agree-
ments were in place between the sponsor and all 
the investigators participating in the trial.
Trial Participants
Patients 12 years of age or older who had a con-
firmed diagnosis of cystic fibrosis and two 
Phe508del alleles, a percentage of the predicted 
FEV1 between 40% and 90% at screening, and 
stable disease, as judged by the investigator, were 
eligible for inclusion. The full inclusion and exclu-
sion criteria are provided in the Supplementary 
Appendix. At screening, all the patients under-
went CFTR genotype confirmation. Values for the 
percentage of predicted FEV1 that were outside the 
range of 40 to 90% were permitted at baseline.
Assessments
The primary end point was the absolute change 
in the percentage of the predicted FEV1 from 
baseline through week 24, including assessments 
at day 15 and weeks 4, 8, 12, 16, and 24. Key 
secondary end points were the relative change in 
the percentage of the predicted FEV1 from base-
line through week 24, the number of pulmonary 
exacerbations through week 24, the absolute 
change from baseline in the body-mass index 
(BMI; the weight in kilograms divided by the 
square of the height in meters) at the week 24 
visit, and the absolute change in the respiratory 
domain score on the Cystic Fibrosis Question-
naire–Revised (CFQ-R; scores are on a scale from 
0 to 100, with higher scores indicating a higher 
patient-reported quality of life with regard to 
respiratory status) from baseline through week 
24. Further details regarding the calculation of 
the absolute and relative changes in the percent-
ages of the predicted FEV1 are provided in the 
Supplementary Appendix.
The safety assessment was based on adverse 
events, clinical laboratory values, electrocardio-
grams, vital signs, pulse oximetry, and spirometry. 
The time to the first pulmonary exacerbation, the 
absolute change in the sweat chloride concentra-
tion (an in vivo marker of CFTR function) from 
baseline through week 24, and the absolute change 
from baseline in the BMI-for-age z score at the 
week 24 visit (in patients <20 years of age at 
screening) were also assessed as secondary end 
points. Assessments were carried out at all trial 
visits (except for the assessments of the sweat 
chloride concentration and CFQ-R score), includ-
ing a safety follow-up visit that occurred 4 weeks 
(within a window of ±7 days) after the receipt of 
the last dose of tezacaftor–ivacaftor or placebo 
in patients who elected not to enroll in the ex-
tension study (see the Study Assessments section 
and Fig. S1 in the Supplementary Appendix).
Statistical Analysis
Efficacy analyses included all the patients who 
had undergone randomization, who had received 
at least one dose of tezacaftor–ivacaftor or place-
bo, and who were homozygous for the Phe508del 
mutation. The primary analysis — the evaluation 
of the difference in the absolute change from 
baseline in the percentage of the predicted FEV1 
through week 24 between the tezacaftor–ivacaftor 
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group and the placebo group — was based on a 
mixed-effects model for repeated measures. The 
percentage of the predicted FEV1 was calculated 
with the use of the standards of Wang et al.30 (for 
female patients 12 to 15 years of age and male 
patients 12 to 17 years of age) or Hankinson et al.31 
(for female patients ≥16 years of age and male 
patients ≥18 years of age). The standard that was 
used for individual patients was changed from 
that of Wang et al. to that of Hankinson et al. if 
they had a birthday during the trial that moved 
them from the younger age group to the older 
age group.
The key secondary efficacy end points, which 
were measured at scheduled time points through 
week 24, were analyzed by means of a mixed-
effects model for repeated measures and (for the 
number of pulmonary exacerbations) a negative 
binomial regression analysis. A fixed-sequence hi-
erarchical testing procedure was used to control the 
overall type I error at a level of 0.05 for the multiple 
hypothesis tests, including the primary and key 
secondary efficacy end points (see the Methods 
section in the Supplementary Appendix). The time 
to the first pulmonary exacerbation was compared 
between the trial groups as a secondary end point 
with the use of a Cox regression model that in-
cluded trial group, sex, age at screening (<18 years 
vs. ≥18 years), and the baseline percentage of the 
predicted FEV1 as covariates. Safety analyses in-
cluded all the patients who had received at least 
one dose of tezacaftor–ivacaftor or placebo, includ-
ing those with ineligible genotypes; these analyses 
were based on data from the period from the first 
dose of trial regimen to the earliest of the follow-
ing: the safety follow-up visit, 28 days after last 
dose of trial regimen for patients who did not have 
a safety follow-up visit, or the day immediately 
before the first dose received in the VX14-661-
110 extension study for patients who enrolled in 
that study.
R esult s
Population of Patients
A total of 510 patients were enrolled and under-
went randomization; 509 patients received at least 
one dose of tezacaftor–ivacaftor (251 patients) or 
placebo (258 patients) (Fig. S2 in the Supplemen-
tary Appendix). One patient who had been ran-
domly assigned to the placebo group did not 
receive any placebo because of a pulmonary ex-
acerbation before the day 1 visit. Five patients 
underwent randomization (3 patients to the 
tezacaftor–ivacaftor group and 2 to the placebo 
group) and received the assigned trial regimen 
but had an ineligible or unconfirmed CFTR geno-
type so were excluded from the efficacy analyses 
but not the safety analyses. Overall, 475 patients 
(235 [93.6%] in the tezacaftor–ivacaftor group 
and 240 [93.0%] in the placebo group) completed 
24 weeks of the trial. A total of 15 patients (2.9%) 
discontinued owing to adverse events (7 [2.8%] 
patients in the tezacaftor–ivacaftor group and 
8 [3.1%] in the placebo group). Sex, age, concomi-
tant medication use, geographic region (North 
America vs. Europe), Pseudomonas aeruginosa infec-
tion, and percentage of the predicted FEV1 were 
well balanced between the two groups (Table 1, 
and Table S1 in the Supplementary Appendix). 
The overall mean (±SD) percentage of the pre-
dicted FEV1 in the trial population was 60.0±15.2%. 
A total of 461 patients (90.6% of those who re-
ceived at least one dose of tezacaftor–ivacaftor or 
placebo) enrolled in the treatment cohort of the 
open-label extension study, including 231 patients 
who had been in the tezacaftor–ivacaftor group 
and 230 who had been in the placebo group.
Clinical Efficacy
A total of 504 patients (248 in the tezacaftor–
ivacaftor group and 256 in the placebo group) 
were included in the efficacy analyses. The use 
of tezacaftor–ivacaftor led to a significantly great-
er absolute change from baseline in the percentage 
of the predicted FEV1 than placebo (least-squares 
mean difference through 24 weeks, 4.0 percentage 
points; 95% confidence interval [CI], 3.1 to 4.8; 
P<0.001) (Table 2). The mean absolute change 
from baseline through week 24 was 3.4 percent-
age points in the tezacaftor–ivacaftor group, as 
compared with −0.6 percentage points in the pla-
cebo group. In the tezacaftor–ivacaftor group, an 
increased percentage of the predicted FEV1 was 
observed at the first assessment (on day 15) and 
was maintained at all trial visits through week 
24 (Fig. 1). The difference was consistent across 
all the prespecified subgroup analyses (Fig. S3 in 
the Supplementary Appendix). The least-squares 
mean difference between groups in the relative 
change from baseline in the percentage of the 
predicted FEV1 through week 24 was 6.8% (95% CI, 
5.3 to 8.3; P<0.001) (Table 2). Absolute and 
relative changes in FEV1 from baseline through 
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week 24 are shown in Table S2 in the Supple-
mentary Appendix.
Patients who received tezacaftor–ivacaftor had 
an annualized estimated event rate of pulmonary 
exacerbations that was significantly lower than 
the rate among those who received placebo (0.64 
vs. 0.99 events per year; rate ratio, 0.65 [repre-
senting a 35% lower rate]; 95% CI, 0.48 to 0.88; 
P = 0.005) (Table 2). The rate of pulmonary exac-
erbations that led to hospitalization or treatment 
with intravenous antibiotic agents (or both) was 
also lower in the tezacaftor–ivacaftor group than 
in the placebo group (0.29 vs. 0.54 events per year; 
rate ratio, 0.53; 95% CI, 0.34 to 0.82). The risk of 
pulmonary exacerbation at 24 weeks was 35% in 
the placebo group and 25% in the tezacaftor–
ivacaftor group, and on the basis of the Cox re-
gression model, the hazard ratio for pulmonary 
exacerbation in the tezacaftor–ivacaftor group, 
as compared with the placebo group, was 0.64 
(95% CI, 0.46 to 0.88) (Fig. 2A).
No significant difference in the BMI at week 
24 was noted between the tezacaftor–ivacaftor 
group and the placebo group (Table 2 and Fig. 2B). 
Therefore, the testing hierarchy for statistical sig-
nificance was broken at this end point. The mean 
BMI was increased from baseline in both the 
tezacaftor–ivacaftor group and the placebo group 
at week 24 (least-squares mean increase, 0.18 
[95% CI, 0.08 to 0.28] and 0.12 [95% CI, 0.03 to 
0.22], respectively).
The least-squares mean difference between 
groups in the CFQ-R respiratory domain score 
through week 24 was 5.1 points (95% CI, 3.2 to 
7.0), favoring tezacaftor–ivacaftor (Table 2 and 
Fig. 2C). In an additional analysis, the percent-
Characteristic
Placebo Group 
(N = 256)
Tezacaftor–Ivacaftor Group 
(N = 248)
Female sex — no. (%) 125 (48.8) 121 (48.8)
Age at screening
Mean — yr 25.7±9.5 26.9±11.2
Distribution — no. (%)
<18 yr 58 (22.7) 58 (23.4)
≥18 yr 198 (77.3) 190 (76.6)
Geographic region — no. (%)
North America 68 (26.6) 59 (23.8)
Europe 188 (73.4) 189 (76.2)
Percentage of predicted FEV1
Mean value 60.4±15.7 59.6±14.7
Distribution — no. (%)
<40% 24 (9.4) 23 (9.3)
≥40% to <70% 152 (59.4) 157 (63.3)
≥70% to ≤90% 73 (28.5) 65 (26.2)
>90% 7 (2.7) 2 (0.8)
Missing data 0 1 (0.4)
Body-mass index† 21.12±2.88 20.96±2.95
Sweat chloride — mmol/liter 100.5±10.2 101.3±10.9
CFQ-R respiratory domain score‡ 69.9±16.6 70.1±16.8
Pseudomonas aeruginosa–positive — no. (%) 182 (71.1) 185 (74.6)
*  Plus–minus values are means ±SD. There were no significant between-group differences in any of these characteristics. 
FEV1 denotes forced expiratory volume in 1 second.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Scores on the Cystic Fibrosis Questionnaire–Revised (CFQ-R) range from 0 to 100, with higher scores indicating a higher 
patient-reported quality of life with regard to respiratory status.
Table 1. Demographic and Clinical Characteristics at Baseline.*
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age of patients who had an increase in the CFQ-R 
respiratory domain score of at least 4 points (i.e., 
the minimal important difference in this age 
group32) was greater in the tezacaftor–ivacaftor 
group than in the placebo group (51.1% vs. 35.7%; 
odds ratio, 2.17; 95% CI, 1.47 to 3.21). The use 
of tezacaftor–ivacaftor resulted in a reduction 
(indicating improvement in CFTR function) in 
the sweat chloride concentration, with a between-
group difference of –10.1 mmol per liter (95% CI, 
−11.4 to −8.8) (Table 2 and Fig. 2D).
Safety
A total of 472 of 509 patients (92.7%) reported 
having at least one adverse event, including 90.4% 
of the patients in the tezacaftor–ivacaftor group 
and 95.0% of those in the placebo group. Most 
events were of mild severity (in 41.8% of patients 
overall) or moderate severity (in 40.9%), and there 
were few grade 3 or 4 events (Table 3). The safety 
profile of tezacaftor–ivacaftor was consistent 
across subgroups that were defined according to 
age, sex, baseline percentage of the predicted FEV1, 
and geographic region (Table S3 in the Supplemen-
tary Appendix). Serious adverse events were re-
ported in 31 patients (12.4%) in the tezacaftor–
ivacaftor group and in 47 (18.2%) in the placebo 
group (Table S4 in the Supplementary Appendix).
No deaths occurred during the trial. Seven 
patients (2.8%) in the tezacaftor–ivacaftor group 
and eight (3.1%) in the placebo group discontin-
ued the trial regimen owing to adverse events. 
Adverse events interrupted the trial regimen in 
two patients (0.8%) in the tezacaftor–ivacaftor 
group and in eight (3.1%) in the placebo group 
(Table S5 in the Supplementary Appendix).
The most commonly observed adverse events 
(>10% incidence in either trial group) were infec-
tive pulmonary exacerbation, cough, headache, 
nasopharyngitis, increased sputum production, 
pyrexia, hemoptysis, oropharyngeal pain, and fa-
tigue. The commonly observed adverse events oc-
curred more frequently in the placebo group than 
in the tezacaftor–ivacaftor group (Table 3; adverse 
events with an incidence of ≥5% in either group 
are shown in Table S6 in the Supplementary Ap-
pendix). Adverse events with both an incidence 
of at least 5% in either group and an incidence 
that was at least 1 percentage point higher in the 
tezacaftor–ivacaftor group than in the placebo 
group were headache, nausea, and nasopharyn-
gitis. Fewer patients in the tezacaftor–ivacaftor 
group than in the placebo group had prespeci-
fied respiratory events of special interest (33 pa-
tients [13.1%]) vs. 41 patients [15.9%]), a trend that 
was consistent across subgroups defined accord-
ing to the baseline percentage of the predicted 
FEV1 (Tables S7 and S8 in the Supplementary Ap-
pendix). There were no discontinuations of the 
trial regimen that were due to respiratory events. 
The incidence of respiratory events was not greater 
at the initiation of tezacaftor–ivacaftor than at the 
initiation of placebo. In the subgroup of patients 
younger than 18 years of age at screening, no 
acute bronchoconstriction or decline in the mean 
postdose FEV1 was noted at 2 hours or 4 hours 
after the administration of tezacaftor–ivacaftor 
(Table S9 in the Supplementary Appendix).
The incidence of abnormal findings on liver-
function tests was low and similar in the two 
groups (Table S10 in the Supplementary Appendix). 
No major differences in electrocardiogram find-
ings, results on pulse oximetry, or vital signs were 
observed between the groups.
Discussion
In this phase 3 trial involving patients with cystic 
fibrosis who were homozygous for the Phe508del 
mutation, tezacaftor–ivacaftor resulted in sig-
nificant improvements in lung function that were 
consistent in all the prespecified subgroups. 
Tezacaftor–ivacaftor also resulted in a significantly 
lower rate of pulmonary exacerbations than pla-
Figure 1. Absolute Change from Baseline in the Percentage of the Predicted 
Forced Expiratory Volume in 1 Second (FEV1).
Data are least-squares means, and I bars indicate 95% confidence intervals. 
The dashed line indicates no change from baseline.
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Figure 2. Proportion of Patients Free from Exacerbation Events and Changes in Body-Mass Index (BMI), Cystic Fibrosis Questionnaire–
Revised (CFQ-R) Respiratory Domain Score, and Sweat Chloride Concentration.
Panel A shows the proportion of patients who were free from events of pulmonary exacerbation. Panel B shows the absolute changes 
from baseline in the BMI (the weight in kilograms divided by the square of the height in meters). Panel C shows the absolute change 
from baseline in the respiratory domain score on the CFQ-R; scores range from 0 to 100, with higher scores indicating a higher patient-
reported quality of life with regard to respiratory status. Panel D shows the sweat chloride concentration; a reduction indicates improve-
ment in CFTR function. The data in Panels B, C, and D are least-squares means, and I bars indicate 95% confidence intervals; the dashed 
line in Panels C and D indicates no change from baseline.
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cebo. The use of tezacaftor–ivacaftor was associ-
ated with a low rate of discontinuation due to 
adverse events, and no new risks attributable to 
tezacaftor–ivacaftor were identified. The rate of 
respiratory adverse events was not higher in the 
tezacaftor–ivacaftor group than in the placebo 
group, which shows that the safety profile for 
tezacaftor–ivacaftor is better than that reported 
for lumacaftor–ivacaftor.
Despite advances in standard-of-care therapy, 
patients with cystic fibrosis continue to lose 
lung function at a rate of approximately 1 to 3% 
per year.33 The majority of patients with cystic 
fibrosis die from their lung disease,5 and the 
median predicted survival is 39 years.34 This 
trial showed a significant effect of tezacaftor–
ivacaftor versus placebo in the absolute change 
from baseline in the percentage of the predicted 
FEV1 through 24 weeks, the primary end point of 
the trial. This effect was rapid in onset, was sus-
tained throughout the trial, and was observed in 
all the prespecified subgroups.
Tezacaftor–ivacaftor was associated with a 
significantly lower frequency of pulmonary exac-
erbations than placebo, as well as a longer time 
to the first exacerbation and a lower rate of ex-
Event
Placebo Group 
(N = 258)
Tezacaftor–Ivacaftor Group 
(N = 251)
number of patients (percent)
Any adverse event 245 (95.0) 227 (90.4)
Adverse event related to trial regimen* 66 (25.6) 64 (25.5)
Adverse event, according to maximum severity
Mild 99 (38.4) 114 (45.4)
Moderate 117 (45.3) 91 (36.3)
Severe 29 (11.2) 21 (8.4)
Life-threatening† 0 1 (0.4)
Grade 3 or 4 adverse event 29 (11.2) 22 (8.8)
Serious adverse event 47 (18.2) 31 (12.4)
Serious adverse event related to the trial regimen* 3 (1.2) 5 (2.0)
Adverse event leading to discontinuation 8 (3.1) 7 (2.8)
Adverse event leading to death 0 0
Most common adverse event‡
Infective pulmonary exacerbation of cystic fibrosis 96 (37.2) 75 (29.9)
Cough 84 (32.6) 66 (26.3)
Headache 37 (14.3) 44 (17.5)
Nasopharyngitis 39 (15.1) 42 (16.7)
Increased sputum production 42 (16.3) 36 (14.3)
Pyrexia 32 (12.4) 28 (11.2)
Hemoptysis 35 (13.6) 26 (10.4)
Oropharyngeal pain 29 (11.2) 22 (8.8)
Fatigue 31 (12.0) 16 (6.4)
*  The determination of relatedness to the trial regimen was made by the investigators.
†  One patient in the tezacaftor–ivacaftor group had a life-threatening serious adverse event of hemoptysis.
‡  The most common adverse events were those that occurred in more than 10% of the patients in either trial group.
Table 3. Adverse Events.
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acerbations that led to hospitalization or the use 
of intravenous antibiotics. Pulmonary exacerba-
tions in patients with cystic fibrosis are associ-
ated with an accelerated decline in lung function, 
a worsening quality of life, an increased health 
care burden, and early death,35-38 and a reduction 
in the frequency of exacerbations is therefore a 
key goal of therapy.
No significant effect on BMI (or on BMI-for-
age z scores) was observed at week 24. This 
finding is in contrast to the increase in BMI that 
was seen in studies of ivacaftor involving chil-
dren and adults and in one of the two pivotal 
studies of lumacaftor–ivacaftor.11,14,21 However, 
modest increases in BMI were observed in both 
the tezacaftor–ivacaftor group and the placebo 
group in the present trial. The mean BMI in the 
two trial groups was in the normal healthy 
range39 (18.5 to 25.0) at baseline, and patients 
were encouraged (per the trial protocol) to follow 
the standard high-fat diet during the trial period. 
These factors may have obscured the effects of 
tezacaftor–ivacaftor on nutritional outcomes. The 
use of tezacaftor–ivacaftor led to an improve-
ment in the respiratory domain scores on the 
CFQ-R (assessed after the testing hierarchy was 
broken), including assessments of cough, sputum 
production, and difficulty breathing — findings 
that indicate that tezacaftor–ivacaftor resulted in 
improved quality of life in these patients. In ad-
dition, the use of tezacaftor–ivacaftor led to a 
rapid and sustained reduction (indicating im-
provement) in the sweat chloride concentration, 
a pharmacodynamic marker of CFTR function.
The incidence of adverse events was similar in 
the tezacaftor–ivacaftor group and the placebo 
group. Adverse events led to the discontinuation 
of the trial regimen in few patients, and no new 
safety signals were seen. In contrast to treatment 
with lumacaftor–ivacaftor in phase 3 and phase 
4 trials,19,21,24-26 tezacaftor–ivacaftor was not as-
sociated with an increased incidence of respira-
tory events or an acute postdose decline in the 
percentage of the predicted FEV1.
In conclusion, this 24-week trial showed the 
efficacy and safety of tezacaftor–ivacaftor in pa-
tients 12 years of age or older who had cystic fibro-
sis and were homozygous for the CFTR Phe508del 
mutation. The improved safety profile of combi-
nation therapy with tezacaftor–ivacaftor, as com-
pared with currently available therapy, in addition 
to its effect on multiple efficacy end points, 
supports its use in a broad range of patients 
with cystic fibrosis.
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